P21 (P021)
Also known as P021
P21 is a tetrapeptide cyclin-dependent kinase (CDK) inhibitor derived from ciliary neurotrophic factor (CNTF) that blocks cell cycle progression by inhibiting CDK-cyclin complexes, triggering apoptosis (programmed cell death) in senescent and cancer cells while allowing healthy cells to continue dividing. It functions as a selective checkpoint regulator, preventing damaged or aged cells from replicating while permitting normal cellular division—essentially quality control for your cellular population.
Route
Subcutaneous injection
Dose range
10 mg – 30 mg
Frequency
Once per day or 5 days on / 2 days off
Cycle length
4–10 weeks
Overview
P21 is a tetrapeptide cyclin-dependent kinase (CDK) inhibitor derived from ciliary neurotrophic factor (CNTF) that blocks cell cycle progression by inhibiting CDK-cyclin complexes, triggering apoptosis (programmed cell death) in senescent and cancer cells while allowing healthy cells to continue dividing. It functions as a selective checkpoint regulator, preventing damaged or aged cells from replicating while permitting normal cellular division—essentially quality control for your cellular population.
Beyond apoptosis, P21 protects DNA through multiple mechanisms including interaction with PCNA (proliferating cell nuclear antigen) to suppress abnormal replication. Research shows it’s particularly valuable for preventing proliferation of aging/senescent cells that accumulate with time and drive age-related disease. Its small size and specific mechanism make it a precise tool lacking the broad immunosuppression of traditional cancer drugs. For anyone interested in cellular quality control and senescence prevention, P21 offers a genetic approach to eliminating dysfunctional cells before they damage surrounding tissue.
Studied benefits
- A neurogenic peptide derived from Ciliary Neurotrophic Factor (CNTF)
- It is highly effective at boosting neurogenesis (the creation of new neurons) and enhancing synaptic plasticity
- It is studied for its potential to improve memory, focus, and recovery from neurodegenerative decline
Reported side effects
- Human data is currently limited to research settings
- Preclinical studies suggest it is well-tolerated, with only minor reports of localized injection-site reactions
Protocol
Dosing Schedule (Subcutaneous / Intramuscular)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Cerebrolysin (60mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: 20 mg/mL).
Promote neuroprotection and neuronal survival by providing neurotrophic support via NGF/BDNF-mimetic activity.
| Phase | Daily Dose (mg) | Draw at 20 mg/mL | Log |
|---|---|---|---|
| Micro-dose (Standard) | 10 mg | 50 units (0.5 mL) | + Log |
| Standard (SubQ) | 20 mg | 100 units (1 mL) | + Log |
| High Dose (IM/IV) | 30 mg | 150 units (1.5 mL) | + Log |
Frequency
Once per day or 5 days on / 2 days off.
Timing
Morning injection (fasted or with food).
Cycle length
4–10 weeks.
Unit calculator
Set your vial and water; the table above updates.
20 mg/mL
6 doses of 10 mg per vial
At the starting dose (10 mg × 7/week for a 4-week cycle) you would use about 280 mg, i.e. 5 × 60 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Prioritize a diet rich in choline, Omega-3 fatty acids, and neuroprotective antioxidants to provide the raw materials for the synaptogenesis and increased BDNF levels stimulated by this CNTF-derived neuropeptide. Engage in daily cognitive challenges, such as learning a new skill or complex problem-solving, to guide the growth of new neural connections toward functional utility. Ensure 7–9 hours of quality sleep to facilitate memory consolidation and allow the glymphatic system to clear metabolic waste from the brain. Avoid neurotoxic substances like excessive alcohol, which can impair the peptide's potential to enhance hippocampal neurogenesis and overall cognitive resilience.
Evidence
Research summaries
Rescue of cognitive-aging by administration of a neurotrophic compound P021
Findings: Reverses memory/learning slips, boosts brain growth factors like BDNF, restores synapse strength in aging brains.
P21 (P021), from ciliary factor, fights age-related brain fog. Old rats got oral doses; learning/memory soared, new neurons grew, BDNF jumped, synapses fixed in hippo/cortex. Myoinositol (age marker) dropped on scans. Safe chronic use. For young minds, prevents early stress dips from exams/games, sharpens recall for classes/tests. Like brain fertilizer for peak teen smarts, future-proofing against decline.
Read the study ↗Clinical evidence of the efficacy and safety of a new multi-peptide anti-aging eye serum
Findings: Cuts wrinkle number/depth/volume, ramps hydration/elasticity/firmness, 75% user satisfaction for smoother skin.
Multi-peptide serum (P21-like) on 32 young adults 28 days: wrinkles shrunk significantly, moisture/ bounce soared steadily. No reactions, easy use. P21 signals collagen for firm youth. Teens erase screen/acne lines early, glowy eyes for pics/class.
Read the study ↗An Open Label Clinical Trial of a Peptide Treatment Serum
Findings: Improves photodamage, boosts neurotransmitter calm for relaxed skin, enhances overall facial vitality.
14-week study 29 women: peptide serum (GABA/peptides) smoothed sun damage, evened tone/texture. Safe, visible glow. P21 analogs fill lines deep. Prevent teen sun scars.
Read the study ↗Collagen-like peptide exhibits a remarkable antiwrinkle effect
Findings: Drops wrinkle count/depth/length 65-80%, deeply acts on skin layers for lasting firmness.
Double-blind: 3% peptide gel on 20 women cut wrinkles statistically (p<0.003), supported by photos/questionnaires. P21 mimics for collagen surge. Youth hack sans irritation.
Read the study ↗More references (4)
- Cognitive Vitality Report: P021 (Ac-DGGLAG-NH2) for Alzheimer’s Disease, 2025
- P21 Peptide: Molecular Properties, Mechanisms, and Research Applications in Neurogenesis, 2024
- Neurotrophic Peptide P021 Enhances Synaptic Plasticity and Memory, 2021
- Chronic Treatment with P021 Rescues Cognitive Impairment in AD Mice, 2017
Identification
Chemistry
- cas
- Not standardized (sequence-based peptide; supplier-dependent designation)
- formula
- C₂₃H₃₆N₆O₇ (approximate based on Ac-DGGLAG-NH₂ structure)
- molecular weight
- Approximately 508-520 g/mol
- sequence
- Ac-Asp-Gly-Gly-Leu-Ala-Gly-NH₂ (with N-terminal acetylation and C-terminal adamantyl modification)
- source
- Synthetic; engineered epitope derived from natural CNTF (amino acids 148-151)
- biosynthesis
- Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS) with post-synthesis modifications
- type
- Linear peptide with N-terminal acetyl group and C-terminal primary amide with adamantyl substitution
Keep exploring
Related peptides
Adamax
- Route
- Subcutaneous
- Dose
- 100 mcg – 300 mcg
- Cycle
- 8–12 weeks
ARA-290
ARA290 · Cibinetide
- Route
- Subcutaneous
- Dose
- 4 mg – 8 mg
- Cycle
- 4–8 weeks
Cortagen
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 4 weeks
Dihexa
- Route
- Topical
- Dose
- 5 mg – 20 mg
- Cycle
- 4–8 weeks